
ViaCyte
Develops cell replacement therapies for diabetes. ViaCyte was acquired by Vertex Pharmaceuticals in 2022.
Develops cell replacement therapies for diabetes. ViaCyte was acquired by Vertex Pharmaceuticals in 2022.
Synthesizes DNA and provides custom DNA products for research and development.
Focused on developing treatments for rare diseases mediated by the complement system. Acquired by Bioverativ in 2017.
Developed high-power semiconductor laser technology for automotive, industrial, and consumer applications, including LiDAR systems. Acquired by Lumentum in 2019.
Offers soil microbiome testing services for agriculture.